Cargando…

Validation of a transparent decision model to rate drug interactions

BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category....

Descripción completa

Detalles Bibliográficos
Autores principales: Far, Elmira, Curkovic, Ivanka, Byrne, Kelly, Roos, Malgorzata, Egloff, Isabelle, Dietrich, Michael, Kirch, Wilhelm, Kullak-Ublick, Gerd-A, Egbring, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598205/
https://www.ncbi.nlm.nih.gov/pubmed/22950884
http://dx.doi.org/10.1186/2050-6511-13-7
_version_ 1782262737404952576
author Far, Elmira
Curkovic, Ivanka
Byrne, Kelly
Roos, Malgorzata
Egloff, Isabelle
Dietrich, Michael
Kirch, Wilhelm
Kullak-Ublick, Gerd-A
Egbring, Marco
author_facet Far, Elmira
Curkovic, Ivanka
Byrne, Kelly
Roos, Malgorzata
Egloff, Isabelle
Dietrich, Michael
Kirch, Wilhelm
Kullak-Ublick, Gerd-A
Egbring, Marco
author_sort Far, Elmira
collection PubMed
description BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category. METHODS: We rated 200 randomly selected potential drug-drug interactions by a transparent decision model developed by our team. The cases were generated from ward round observations and physicians’ queries from an outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a standard interaction database, and thus validated the model. RESULTS: The decision model rated consistently with the standard database and the pharmacologist in 94 and 156 cases, respectively. In two cases the model decision required correction. Following removal of systematic model construction differences, the DM was fully consistent with other rating systems. CONCLUSION: The decision model reproducibly rates interactions and elucidates systematic differences. We propose to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable physicians to interpret the ratings in a clinical context.
format Online
Article
Text
id pubmed-3598205
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35982052013-03-16 Validation of a transparent decision model to rate drug interactions Far, Elmira Curkovic, Ivanka Byrne, Kelly Roos, Malgorzata Egloff, Isabelle Dietrich, Michael Kirch, Wilhelm Kullak-Ublick, Gerd-A Egbring, Marco BMC Pharmacol Toxicol Research Article BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category. METHODS: We rated 200 randomly selected potential drug-drug interactions by a transparent decision model developed by our team. The cases were generated from ward round observations and physicians’ queries from an outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a standard interaction database, and thus validated the model. RESULTS: The decision model rated consistently with the standard database and the pharmacologist in 94 and 156 cases, respectively. In two cases the model decision required correction. Following removal of systematic model construction differences, the DM was fully consistent with other rating systems. CONCLUSION: The decision model reproducibly rates interactions and elucidates systematic differences. We propose to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable physicians to interpret the ratings in a clinical context. BioMed Central 2012-08-20 /pmc/articles/PMC3598205/ /pubmed/22950884 http://dx.doi.org/10.1186/2050-6511-13-7 Text en Copyright ©2012 Far et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Far, Elmira
Curkovic, Ivanka
Byrne, Kelly
Roos, Malgorzata
Egloff, Isabelle
Dietrich, Michael
Kirch, Wilhelm
Kullak-Ublick, Gerd-A
Egbring, Marco
Validation of a transparent decision model to rate drug interactions
title Validation of a transparent decision model to rate drug interactions
title_full Validation of a transparent decision model to rate drug interactions
title_fullStr Validation of a transparent decision model to rate drug interactions
title_full_unstemmed Validation of a transparent decision model to rate drug interactions
title_short Validation of a transparent decision model to rate drug interactions
title_sort validation of a transparent decision model to rate drug interactions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598205/
https://www.ncbi.nlm.nih.gov/pubmed/22950884
http://dx.doi.org/10.1186/2050-6511-13-7
work_keys_str_mv AT farelmira validationofatransparentdecisionmodeltoratedruginteractions
AT curkovicivanka validationofatransparentdecisionmodeltoratedruginteractions
AT byrnekelly validationofatransparentdecisionmodeltoratedruginteractions
AT roosmalgorzata validationofatransparentdecisionmodeltoratedruginteractions
AT egloffisabelle validationofatransparentdecisionmodeltoratedruginteractions
AT dietrichmichael validationofatransparentdecisionmodeltoratedruginteractions
AT kirchwilhelm validationofatransparentdecisionmodeltoratedruginteractions
AT kullakublickgerda validationofatransparentdecisionmodeltoratedruginteractions
AT egbringmarco validationofatransparentdecisionmodeltoratedruginteractions